249.39 USD
+4.68 (+1.91%)
249.39 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to KRYS. KRYS was compared to 530 industry peers in the Biotechnology industry. While KRYS has a great health rating, its profitability is only average at the moment. KRYS is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
KRYS had positive earnings in the past year.
KRYS had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: KRYS reported negative net income in multiple years.
In the past 5 years KRYS reported 4 times negative operating cash flow.
1.2 Ratios
KRYS has a better Return On Assets (16.04%) than 95.85% of its industry peers.
Looking at the Return On Equity, with a value of 17.48%, KRYS belongs to the top of the industry, outperforming 95.28% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 12.28%, KRYS belongs to the top of the industry, outperforming 95.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.04% | ||
| ROE | 17.48% | ||
| ROIC | 12.28% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of KRYS (53.30%) is better than 98.30% of its industry peers.
The Operating Margin of KRYS (42.40%) is better than 99.06% of its industry peers.
With an excellent Gross Margin value of 94.26%, KRYS belongs to the best of the industry, outperforming 94.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.4% | ||
| PM (TTM) | 53.3% | ||
| GM | 94.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KRYS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for KRYS has been increased compared to 1 year ago.
Compared to 5 years ago, KRYS has more shares outstanding
KRYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
KRYS has an Altman-Z score of 43.95. This indicates that KRYS is financially healthy and has little risk of bankruptcy at the moment.
KRYS has a Altman-Z score of 43.95. This is amongst the best in the industry. KRYS outperforms 96.23% of its industry peers.
KRYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 43.95 |
ROIC/WACC1.39
WACC8.81%
2.3 Liquidity
KRYS has a Current Ratio of 10.14. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of KRYS (10.14) is better than 81.13% of its industry peers.
A Quick Ratio of 9.73 indicates that KRYS has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 9.73, KRYS belongs to the best of the industry, outperforming 80.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.14 | ||
| Quick Ratio | 9.73 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 276.84% over the past year.
Looking at the last year, KRYS shows a very strong growth in Revenue. The Revenue has grown by 54.51%.
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
Revenue 1Y (TTM)54.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%
3.2 Future
The Earnings Per Share is expected to grow by 58.10% on average over the next years. This is a very strong growth
KRYS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.67% yearly.
EPS Next Y108.95%
EPS Next 2Y63.81%
EPS Next 3Y46.21%
EPS Next 5Y58.1%
Revenue Next Year33.79%
Revenue Next 2Y37.74%
Revenue Next 3Y36.66%
Revenue Next 5Y31.67%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 37.39, which means the current valuation is very expensive for KRYS.
Based on the Price/Earnings ratio, KRYS is valued cheaper than 91.89% of the companies in the same industry.
When comparing the Price/Earnings ratio of KRYS to the average of the S&P500 Index (27.17), we can say KRYS is valued slightly more expensively.
A Price/Forward Earnings ratio of 31.08 indicates a quite expensive valuation of KRYS.
KRYS's Price/Forward Earnings ratio is rather cheap when compared to the industry. KRYS is cheaper than 92.08% of the companies in the same industry.
KRYS is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.79, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.39 | ||
| Fwd PE | 31.08 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, KRYS is valued cheaply inside the industry as 91.51% of the companies are valued more expensively.
93.02% of the companies in the same industry are more expensive than KRYS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.68 | ||
| EV/EBITDA | 37.76 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of KRYS may justify a higher PE ratio.
A more expensive valuation may be justified as KRYS's earnings are expected to grow with 46.21% in the coming years.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y63.81%
EPS Next 3Y46.21%
5. Dividend
5.1 Amount
KRYS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
249.39
+4.68 (+1.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners96.44%
Inst Owner Change0%
Ins Owners11.65%
Ins Owner Change-2.53%
Market Cap7.23B
Revenue(TTM)373.16M
Net Income(TTM)198.91M
Analysts84.44
Price Target226.9 (-9.02%)
Short Float %11%
Short Ratio8.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.19%
Min EPS beat(2)12.14%
Max EPS beat(2)140.23%
EPS beat(4)3
Avg EPS beat(4)41.54%
Min EPS beat(4)-13.89%
Max EPS beat(4)140.23%
EPS beat(8)4
Avg EPS beat(8)30.53%
EPS beat(12)5
Avg EPS beat(12)2.39%
EPS beat(16)7
Avg EPS beat(16)0.53%
Revenue beat(2)2
Avg Revenue beat(2)2.66%
Min Revenue beat(2)2.42%
Max Revenue beat(2)2.89%
Revenue beat(4)2
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)2.89%
Revenue beat(8)4
Avg Revenue beat(8)4.55%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.7%
EPS NY rev (1m)0%
EPS NY rev (3m)22.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.39 | ||
| Fwd PE | 31.08 | ||
| P/S | 19.38 | ||
| P/FCF | 43.68 | ||
| P/OCF | 41.05 | ||
| P/B | 6.36 | ||
| P/tB | 6.36 | ||
| EV/EBITDA | 37.76 |
EPS(TTM)6.67
EY2.67%
EPS(NY)8.02
Fwd EY3.22%
FCF(TTM)5.71
FCFY2.29%
OCF(TTM)6.08
OCFY2.44%
SpS12.87
BVpS39.24
TBVpS39.24
PEG (NY)0.34
PEG (5Y)N/A
Graham Number76.74
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.04% | ||
| ROE | 17.48% | ||
| ROCE | 13.77% | ||
| ROIC | 12.28% | ||
| ROICexc | 33.76% | ||
| ROICexgc | 33.76% | ||
| OM | 42.4% | ||
| PM (TTM) | 53.3% | ||
| GM | 94.26% | ||
| FCFM | 44.37% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 213.54% | ||
| Cap/Sales | 2.84% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 107.96% | ||
| Profit Quality | 83.25% | ||
| Current Ratio | 10.14 | ||
| Quick Ratio | 9.73 | ||
| Altman-Z | 43.95 |
F-Score7
WACC8.81%
ROIC/WACC1.39
Cap/Depr(3y)537.2%
Cap/Depr(5y)976.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
EPS Next Y108.95%
EPS Next 2Y63.81%
EPS Next 3Y46.21%
EPS Next 5Y58.1%
Revenue 1Y (TTM)54.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%
Revenue Next Year33.79%
Revenue Next 2Y37.74%
Revenue Next 3Y36.66%
Revenue Next 5Y31.67%
EBIT growth 1Y143.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year178.74%
EBIT Next 3Y82.59%
EBIT Next 5YN/A
FCF growth 1Y239.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y269.59%
OCF growth 3YN/A
OCF growth 5YN/A
KRYSTAL BIOTECH INC / KRYS FAQ
Can you provide the ChartMill fundamental rating for KRYSTAL BIOTECH INC?
ChartMill assigns a fundamental rating of 6 / 10 to KRYS.
What is the valuation status for KRYS stock?
ChartMill assigns a valuation rating of 6 / 10 to KRYSTAL BIOTECH INC (KRYS). This can be considered as Fairly Valued.
What is the profitability of KRYS stock?
KRYSTAL BIOTECH INC (KRYS) has a profitability rating of 6 / 10.
Can you provide the PE and PB ratios for KRYS stock?
The Price/Earnings (PE) ratio for KRYSTAL BIOTECH INC (KRYS) is 37.39 and the Price/Book (PB) ratio is 6.36.
What is the financial health of KRYSTAL BIOTECH INC (KRYS) stock?
The financial health rating of KRYSTAL BIOTECH INC (KRYS) is 9 / 10.